Prospective cohort study of children born to human immunodeficiency virus-infected mothers, 1985 through 1997: Trends in the risk of vertical transmission, mortality and acquired immunodeficiency syndrome indicator diseases in the era before highly active antiretroviral therapy

Pediatric Infectious Disease Journal

Volumn 19, Issue 7, 2000, Pages 618-624

  Simpson, B Joyce ^a   Shapiro, Eugene D ^b   Andiman, Warren A ^b  

^a YALE NEW HAVEN HOSPITAL   (United States)

^b YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Acquired immunodeficiency syndrome; Morbidity; Mortality; Pediatric human immunodeficiency virus infection; Survival; Vertical transmission

Indexed keywords

ANTIRETROVIRUS AGENT;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ARTICLE; COHORT ANALYSIS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFANT; MAJOR CLINICAL STUDY; MATERNAL DISEASE; MORTALITY; MYCOBACTERIOSIS; PNEUMOCYSTIS PNEUMONIA; PRIORITY JOURNAL; RISK; VERTICAL TRANSMISSION; WASTING SYNDROME;

ACQUIRED IMMUNODEFICIENCY SYNDROME; ADOLESCENT; ADULT; CONNECTICUT; DISEASE PROGRESSION; DISEASE TRANSMISSION, VERTICAL; FEMALE; HIV INFECTIONS; HIV WASTING SYNDROME; HUMANS; INFANT; PNEUMONIA, PNEUMOCYSTIS; PREGNANCY; PREGNANCY COMPLICATIONS, INFECTIOUS; PROSPECTIVE STUDIES; RISK FACTORS; TUBERCULOSIS;

EID: 0033928043     PISSN: 08913668     EISSN: None     Source Type: Journal    
DOI: 10.1097/00006454-200007000-00007     Document Type: Article

References (39)

1. Blanche S, Newell ML, Mayaux MJ, et al. Morbidity and mortality in European children vertically infected by HIV-1: The French Pediatric Infection Study Group and European Collaborative Study. J AIDS Hum Retrovirol 1997;14:442-50.
2. Kline MW, Paul ME, Bohannon B, et al. Characteristics of children surviving to 5 years of age or older with vertically acquired HIV infection. Pediatr AIDS HIV Infect 1995;6: 350-3.
3. Andiman WA, Simpson BJ, Olson B, Dember L, Silva TJ, Miller G. Rate of transmission of human immunodeficiency virus type 1 infection from mother to child and short-term outcome of neonatal infection. Am J Dis Child 1990;144:758-66.
4. Scarlatti G. Paediatric HIV infection. Lancet 1996;348: 863-8.
5. Tovo PA, de Martino M, Gabiano C, et al. Prognostic factors and survival in children with perinatal HIV-1 infection. Lancet 1992;339:1249-53.
6. Blanche S, Tardieu M, Dulliege A, et al. Longitudinal study of 94 symptomatic infants with perinatally acquired human immunodeficiency virus infection: evidence for a bimodal expression of clinical and biological symptoms. Am J Dis Child 1990;144:1210-5.
7. Krasinski K, Borkowsky W, Holzman RS. Prognosis of human immunodeficiency virus infection in children and adolescents. Pediatr Infect Dis J 1989;8:216-20.
8. Barnhart HX, Caldwell MB, Thomas P, et al. Natural history of human immunodeficiency virus disease in perinatally infected children: an analysis from the pediatric spectrum of disease project. Pediatrics 1996;97:710-16.
9. Kline MW, Bohannon B, Kozinetz CA, Rosenblatt HM, Shearer WT. Characteristics of human immunodeficiency virus-associated mortality in pediatric patients with vertically transmitted infections. Pediatr Infect Dis J 1992;11: 676-7.
10. The European Collaborative Study. Natural history of vertically acquired immunodeficiency virus-1 infection. Pediatrics 1994;94:815-9.
11. Falloon J, Eddy J, Wiener L, Pizzo PA. Human immunodeficiency virus infection in children. J Pediatr 1989;114:1-30.
12. Italian Register for HIV infection in Children. Features of children perinatally infected with HIV-1 surviving longer than 5 years. Lancet. 1994;343:191-5.
13. Morris CR, Araba-Owoyele L, Spector S, Maldonado Y. Disease patterns and survival after acquired immunodeficiency syndrome diagnosis in human immunodeficiency virus-infected children. Pediatr Infect Dis J 1996;15:321-8.
14. Scott GB, Hutto C, Makuch RW, et al. Survival in children with perinatally acquired human immunodeficiency virus type 1 infection. N Engl J Med 1989;321:1791-814.
15. Volberding PA, Lagakos SW, Koch MA, et al. Zidovudine in asymptomatic immunodeficiency virus infection. N Engl J Med 1990;332:941-9.
16. Simpson BJ, Shapiro ED, Andiman WA. Reduction in the risk of vertical transmission of HIV-1 associated with treatment of pregnant women with orally-administered zidovudine alone. J AIDS Hum Retrovirol 1997;14:145-52.
17. CDC. Recommendations of the U. S. Public Health Service Task Force on the use of zidovudine to reduce perinatal transmission of human immunodeficiency virus. MMWR 1994;43(RR-11):1-20.
18. CDC. Guidelines for prophylaxis against Pneumocystis carinii pneumonia for children infected with human immunodeficiency virus. MMWR 1991;40(RR-2):1-13.
19. CDC. 1995 Revised guidelines for prophylaxis against Pneumocystis carinii pneumonia for children infected with or perinatally exposed to human immunodeficiency virus. MMWR 1995;44(RR-4):1-11.
20. CDC. USPHS/IDSA guidelines for the prevention of opportunistic infections in persons infected with human immunodeficiency virus: a summary. MMWR 1995;44(RR-8).
21. USPHS/IDSA report on the prevention of opportunistic infections in persons infected with human immunodeficiency virus. Pediatrics 1998;102:1063-85.
22. Andiman WA, Silva TJ, Shapiro ED, O'Connor T, Olson B. Predictive value of the human immunodeficiency virus 1 antigen test in children born to infected mothers. Pediatr Infect Dis J 1992;11:436-40.
23. Ikeda M, Andiman WA, Mezger J, Shapiro ED, Miller G. Quantitative leukoviremia and immune complex-dissociated antigenemia as predictors of infection status in children born to HIV-1 seropositive mothers. J Pediatr 1993;122:524-31.
24. Simpson BJ, Andiman WA. Difficulties in assigning human immunodeficiency virus-1 infection and seroreversion status in a cohort of HIV-exposed children using serologic criteria established by the Centers for Disease Control and Prevention. Pediatrics 1994;93:840-2.
25. CDC. Classification system for human immunodeficiency virus (HIV) infection in children under 13 years of age. MMWR 1987;36:225-30, 235.
26. CDC. 1994 Revised classification system for human immunodeficiency virus infection in children less than 13 years of age. MMWR 1994;43(RR-12):1-19.
27. U. S. Public Health Service. Pediatric HIV/AIDS confidential case report form. CDC 50.42B 03/95.
28. Mehta C, Patel N. StatXact. Cambridge, MA: Cytel Software, 1991.
29. Gustafson TL. True Epistat. 5th ed. Richardson, TX: Epistat Services, 1994.
30. Mantel N, Haenszel W. Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst 1959;22:719-48.
31. International Perinatal HIV Group. The mode of delivery and the risk of vertical transmission of human immunodeficiency virus type 1: a meta-analysis of 15 prospective cohort studies. N Engl J Med 1999;340:977-87.
32. Palella FJ Jr, Delaney KM, Moorman AC, et al. Declining morbidity among patients with advanced human immunodeficiency virus infection. N Engl J Med 1998;338:853-60.
33. Mocroft A, Vella S, Benfield TL, et al. Changing patterns of mortality across Europe in patients infected with HIV-1. Lancet 1998;352:1725-30.
34. Forrest DM, Seminari E, Hogg RS, et al. The incidence and spectrum of AIDS-defining illnesses in persons treated with antiretroviral drugs. Clin Infect Dis 1998;27:1379-85.
35. Frederick T, Caldwell B, Mascola L, et al. Trends in pediatric AIDS-defining conditions in the USA [Abstract 5222]. Proceedings of the XI International Conference on AIDS, Vancouver, BC, July 7 to 12, 1996.
36. Wiktor SZ, Ekpini E, Karon JM, et al. Short course of zidovudine for prevention of mother-to-child transmission of HIV-1 in Abidjan, Côte d'Ivoire: a randomized trial. Lancet 1999;353:781-5.
37. Dabis F, Msellati P, Meda N, et al. Six-month efficacy, tolerance, and acceptability of a short regimen of oral zidovudine to reduce vertical transmission of HIV in breastfed children in Côte d'Ivoire and Burkina Faso: a double blind placebo-controlled multicentre study. Lancet 1999;353:786-92.
38. Shaffer N, Chuachoowong R, Mock PA, et al. Short course zidovudine for perinatal HIV-1 transmission in Bangkok, Thailand: a randomised controlled trial. Lancet 1999;353: 773-80.
39. Guay LA, Musoke P, Fleming T, et al. Intrapartum and neonatal single-dose nevirapine compared to zidovudine for prevention of mother-to-child transmission of HIV-1 in Kampala, Uganda: HIVNET 012 randomised trial. Lancet 1999; 354:795-802.